145 related articles for article (PubMed ID: 22450971)
1. Divalent metals and pH alter raltegravir disposition in vitro.
Moss DM; Siccardi M; Murphy M; Piperakis MM; Khoo SH; Back DJ; Owen A
Antimicrob Agents Chemother; 2012 Jun; 56(6):3020-6. PubMed ID: 22450971
[TBL] [Abstract][Full Text] [Related]
2. Predicting intestinal absorption of raltegravir using a population-based ADME simulation.
Moss DM; Siccardi M; Back DJ; Owen A
J Antimicrob Chemother; 2013 Jul; 68(7):1627-34. PubMed ID: 23515248
[TBL] [Abstract][Full Text] [Related]
3. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
Kiser JJ; Bumpass JB; Meditz AL; Anderson PL; Bushman L; Ray M; Predhomme JA; Rower J; Mawhinney S; Brundage R
Antimicrob Agents Chemother; 2010 Dec; 54(12):4999-5003. PubMed ID: 20921313
[TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
5. Apical acidity decreases inhibitory effect of omeprazole on Mg(2+) absorption and claudin-7 and -12 expression in Caco-2 monolayers.
Thongon N; Krishnamra N
Exp Mol Med; 2012 Nov; 44(11):684-93. PubMed ID: 22940736
[TBL] [Abstract][Full Text] [Related]
6. A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.
Moss DM; Curley P; Shone A; Siccardi M; Owen A
J Antimicrob Chemother; 2014 Dec; 69(12):3275-81. PubMed ID: 25114168
[TBL] [Abstract][Full Text] [Related]
7. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers.
Wang L; Soon GH; Seng KY; Li J; Lee E; Yong EL; Goh BC; Flexner C; Lee L
Antimicrob Agents Chemother; 2011 Sep; 55(9):4090-5. PubMed ID: 21746959
[TBL] [Abstract][Full Text] [Related]
9. Effects of omeprazole on plasma levels of raltegravir.
Iwamoto M; Wenning LA; Nguyen BY; Teppler H; Moreau AR; Rhodes RR; Hanley WD; Jin B; Harvey CM; Breidinger SA; Azrolan N; Farmer HF; Isaacs RD; Chodakewitz JA; Stone JA; Wagner JA
Clin Infect Dis; 2009 Feb; 48(4):489-92. PubMed ID: 19143531
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
[TBL] [Abstract][Full Text] [Related]
11. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
[TBL] [Abstract][Full Text] [Related]
12. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
Serfaty-Lacrosniere C; Wood RJ; Voytko D; Saltzman JR; Pedrosa M; Sepe TE; Russell RR
J Am Coll Nutr; 1995 Aug; 14(4):364-8. PubMed ID: 8568113
[TBL] [Abstract][Full Text] [Related]
13. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine.
Chae HW; Kim IW; Jin HE; Kim DD; Chung SJ; Shim CK
Arch Pharm Res; 2008 Jan; 31(1):103-10. PubMed ID: 18277615
[TBL] [Abstract][Full Text] [Related]
14. A conventional LC-MS method developed for the determination of plasma raltegravir concentrations.
Takahashi M; Konishi M; Kudaka Y; Okumura N; Hirano A; Terahata N; Banno K; Kaneda T
Biol Pharm Bull; 2008 Aug; 31(8):1601-4. PubMed ID: 18670096
[TBL] [Abstract][Full Text] [Related]
15. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Iwamoto M; Kassahun K; Troyer MD; Hanley WD; Lu P; Rhoton A; Petry AS; Ghosh K; Mangin E; DeNoia EP; Wenning LA; Stone JA; Gottesdiener KM; Wagner JA
J Clin Pharmacol; 2008 Feb; 48(2):209-14. PubMed ID: 18077730
[TBL] [Abstract][Full Text] [Related]
16. Drug-drug interactions with raltegravir.
Burger DM
Eur J Med Res; 2009 Nov; 14 Suppl 3(Suppl 3):17-21. PubMed ID: 19959412
[TBL] [Abstract][Full Text] [Related]
17. Divalent cations regulate acidity within the lumen and tubulovesicle compartment of gastric parietal cells.
Gerbino A; Hofer AM; McKay B; Lau BW; Soybel DI
Gastroenterology; 2004 Jan; 126(1):182-95. PubMed ID: 14699499
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing.
Cattaneo D; Baldelli S; Cerea M; Landonio S; Meraviglia P; Simioni E; Cozzi V; Fucile S; Gazzaniga A; Clementi E; Galli M; Rizzardini G; Gervasoni C
Antimicrob Agents Chemother; 2012 Dec; 56(12):6132-6. PubMed ID: 22964253
[TBL] [Abstract][Full Text] [Related]
19. Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry.
Jourdil JF; Bartoli M; Stanke-Labesque F
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3734-8. PubMed ID: 19744899
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method.
Wang LZ; Lee LS; Thuya WL; Soon GH; Kong LR; Nye PL; Lee EJ; Flexner C; Goh BC
J Mass Spectrom; 2011 Feb; 46(2):202-8. PubMed ID: 21259392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
